Manpreet Kalkat

Manpreet Kalkat

Auto-generated profile, based on publicly available information

Manpreet Kalkat

University of Toronto, Toronto, Ontario, Canada

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 May 2017 in Genes
Verified
Journal Article
Open access
PDF file
MKManpreet Kalkat
Manpreet Kalkat
JMJason De Melo
Jason De Melo
KHKatherine Ashley Hickman
Katherine Ashley Hickman
CLCorey Lourenco
Corey Lourenco
CRCornelia Redel
Cornelia Redel
LPLinda Z. Penn
Linda Z. Penn
MYC regulates a complex biological program by transcriptionally activating and repressing its numerous target genes. As such, MYC is a master regulator of many processes, including cell cycle entry, ribosome biogenesis, and metabolism. In cancer, the activity of the MYC transcriptional network is frequently deregulated, contributing to the initiation and maintenance of disease. Deregulation often leads to constitutive overexpression of MYC, which can be achieved through gross genetic abnormalities, including copy number alterations, chromosomal translocations, increased enhancer activity, or through aberrant signal transduction leading to increased MYC transcription or increased MYC mRNA and protein stability. Herein, we summarize the frequency and modes of MYC deregulation and describe both well-established and more recent findings in a variety of cancer types. Notably, these studies have highlighted that with an increased appreciation for the basic mechanisms deregulating MYC in cancer, new therapeutic vulnerabilities can be discovered and potentially exploited for the inhibition of this potent oncogene in cancer.

1 December 2018 in Molecular Cell
Verified
Journal Article
Closed access
MKManpreet Kalkat
Manpreet Kalkat
DRDiana Resetca
Diana Resetca
CLCorey Lourenco
Corey Lourenco
PCPak-Kei Chan
Pak-Kei Chan
YWYong Wei
Yong Wei
LPLinda Z. Penn
Linda Z. Penn

1 April 2015 in Journal of Proteomics
Verified
Journal Article
Closed access
DDDharmendra Dingar
Dharmendra Dingar
MKManpreet Kalkat
Manpreet Kalkat
PCPak-Kei Chan
Pak-Kei Chan
TSTharan Srikumar
Tharan Srikumar
SBSwneke D. Bailey
Swneke D. Bailey
BRBrian Raught
Brian Raught

13 July 2022 in Cell Genomics
Verified
Journal Article
Open access
WZWanding Zhou
Wanding Zhou
THToshinori Hinoue
Toshinori Hinoue
BBBret Barnes
Bret Barnes
OMOwen Mitchell
Owen Mitchell
WIWaleed Iqbal
Waleed Iqbal
PLPeter W. Laird
Peter W. Laird
We have developed a mouse DNA methylation array that contains 296,070 probes representing the diversity of mouse DNA methylation biology. We present a mouse methylation atlas as a rich reference resource of 1,239 DNA samples encompassing distinct tissues, strains, ages, sexes, and pathologies. We describe applications for comparative epigenomics, genomic imprinting, epigenetic inhibitors, patient-derived xenograft assessment, backcross tracing, and epigenetic clocks. We dissect DNA methylation processes associated with differentiation, aging, and tumorigenesis. Notably, we find that tissue-specific methylation signatures localize to binding sites for transcription factors controlling the corresponding tissue development. Age-associated hypermethylation is enriched at regions of Polycomb repression, while hypomethylation is enhanced at regions bound by cohesin complex members. ApcMin/+ polyp-associated hypermethylation affects enhancers regulating intestinal differentiation, while hypomethylation targets AP-1 binding sites. This Infinium Mouse Methylation BeadChip (version MM285) is widely accessible to the research community and will accelerate high-sample-throughput studies in this important model organism.

1 September 2014 in Cancer Research
Verified
Journal Article
Closed access
PDF file
APAleksandra Pandyra
Aleksandra Pandyra
PMPeter J. Mullen
Peter J. Mullen
MKManpreet Kalkat
Manpreet Kalkat
RYRosemary Yu
Rosemary Yu
JPJanice T. Pong
Janice T. Pong
LPLinda Z. Penn
Linda Z. Penn
New therapies are urgently needed for hematologic malignancies, especially in patients with relapsed acute myelogenous leukemia (AML) and multiple myeloma. We and others have previously shown that FDA-approved statins, which are used to control hypercholesterolemia and target the mevalonate pathway (MVA), can trigger tumor-selective apoptosis. Our goal was to identify other FDA-approved drugs that synergize with statins to further enhance the anticancer activity of statins in vivo. Using a screen composed of other FDA approved drugs, we identified dipyridamole, used for the prevention of cerebral ischemia, as a potentiator of statin anticancer activity. The statin–dipyridamole combination was synergistic and induced apoptosis in multiple myeloma and AML cell lines and primary patient samples, whereas normal peripheral blood mononuclear cells were not affected. This novel combination also decreased tumor growth in vivo. Statins block HMG-CoA reductase (HMGCR), the rate-limiting enzyme of the MVA pathway. Dipyridamole blunted the feedback response, which upregulates HMGCR and HMG-CoA synthase 1 (HMGCS1) following statin treatment. We further show that dipyridamole inhibited the cleavage of the transcription factor required for this feedback regulation, sterol regulatory element–binding transcription factor 2 (SREBF2, SREBP2). Simultaneously targeting the MVA pathway and its restorative feedback loop is preclinically effective against hematologic malignancies. This work provides strong evidence for the immediate evaluation of this novel combination of FDA-approved drugs in clinical trials. Cancer Res; 74(17); 4772–82. ©2014 AACR.

22 August 2015 in Oncotarget
Verified
Journal Article
Open access
PDF file
APAleksandra A. Pandyra
Aleksandra A. Pandyra
PMPeter J. Mullen
Peter J. Mullen
CGCarolyn A. Goard
Carolyn A. Goard
EEElke Ericson
Elke Ericson
PSPiyush Sharma
Piyush Sharma
LPLinda Z. Penn
Linda Z. Penn
Genome-wide RNAi analysis reveals that simultaneous inhibition of specific mevalonate pathway genes potentiates tumor cell death